Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125298841 | 12529884 | 1 | I | 20150619 | 0 | 20160705 | 20160705 | DIR | 82.00 | YR | M | N | 224.00000 | LBS | 20160702 | N | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125298841 | 12529884 | 1 | PS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 TABLET(S) IN THE MORNING TAKEN BY MOUTH | N | D | 0 | 30 | DF | COATED TABLET | |||||
| 125298841 | 12529884 | 3 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 5 | C | TRICOR | FENOFIBRATE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 7 | C | FINASTERIDE. | FINASTERIDE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 9 | C | FOFINOPRIL | 2 | 0 | |||||||||||||
| 125298841 | 12529884 | 11 | C | GLIPIZIDE XL | GLIPIZIDE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 13 | C | HCTX | 2 | 0 | |||||||||||||
| 125298841 | 12529884 | 15 | C | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 17 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 19 | C | METOPROLOL. | METOPROLOL | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 21 | C | TERZOSIN | 2 | 0 | |||||||||||||
| 125298841 | 12529884 | 23 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 25 | C | IRON | IRON | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 27 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 29 | C | MVI | VITAMINS | 1 | 0 | ||||||||||||
| 125298841 | 12529884 | 31 | C | VITAMIN C | ASCORBIC ACID | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125298841 | 12529884 | 1 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125298841 | 12529884 | DE |
| 125298841 | 12529884 | LT |
| 125298841 | 12529884 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125298841 | 12529884 | Ascites | |
| 125298841 | 12529884 | Bladder cancer | |
| 125298841 | 12529884 | Blood urine present | |
| 125298841 | 12529884 | Metastases to abdominal cavity | |
| 125298841 | 12529884 | Metastases to lymph nodes | |
| 125298841 | 12529884 | Pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125298841 | 12529884 | 1 | 20080409 | 20150619 | 0 |